TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02036398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double J stent without nephrostomy
Description: Double J stent only left at the end of the procedure without placement of a nephrostomy tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double J stent without nephrostomy
Description: Double J stent only left at the end of the procedure without placement of a nephrostomy tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nephrostomy tube and double J stent
Description: Double J stent and nephrostomy tube left at end of procedure
Study: NCT04425096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin to skin contact
Description: Skin to skin contact
Study: NCT02549300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue massage
Description: It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
Study: NCT04038008

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole
Description: Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole
Description: Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.

Intervention type: DRUG
Group type: OTHER
Intervention: Diflucan®
Description: Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.

Intervention type: DRUG
Group type: OTHER
Intervention: Diflucan®
Description: Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
Study: NCT01654796

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Field Magnetic Stimulation (LFMS)
Description: The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham LFMS
Description: Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
Study: NCT04442750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: The patient will receive 30ml bupivacain 0.25% in erector spinae block
Study: NCT03752073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-cervical cervical balloon
Description: Insertion of Foley Catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hygroscopic cervical dilator
Description: Insertion of Dilapan-s
Study: NCT02224079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB 722 CL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hydroxypropyl-beta-cyclodextrin (HPβCD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydroxypropyl-beta-cyclodextrin (HPβCD)
Study: NCT01934231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
Study: NCT03106402

Intervention type: DRUG
Intervention: topical bromfenac sodium hydrate
Study: NCT01654796

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham LFMS
Description: Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
Study: NCT04694456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytokines dosage
Description: Mesure of cytokines concentration in serum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: test of walk
Description: patient must walk during 6 minutes on a flat surface

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual muscular test
Description: test performed to evaluate the patient muscular weakness

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motrice fonction mesurement
Description: scale allowing the evaluation of patient posture and upper body movements
Study: NCT00772070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
Description: 0.05 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
Description: 0.05 mL, Subcutaneous
Study: NCT01323738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
Study: NCT02515032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrifriend Cachexia
Description: 2 daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric placebo
Description: 2 daily for 12 weeks
Study: NCT01554969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine + ganetespib
Description: Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily.
Study: NCT02524964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium tanshinone IIA sulfonate
Description: eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: equivalent volume of sodium chloride solution
Study: NCT02068339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oltipraz 1 (90mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oltipraz 2 (120mg)
Study: NCT02914847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Description: Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
Study: NCT01490788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: TNX-102 2.4 mg - 1 gelcap once under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
Study: NCT05344638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS (Experimental)
Description: tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AGU (Active Comparator)
Description: tid
Study: NCT02689687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support partner
Description: Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement incentives
Description: Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic pill bottle
Description: Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bluetooth scale
Description: Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
Study: NCT01043510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: 0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: 0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
Study: NCT00491426

Intervention type: DRUG
Intervention: Ampicillin
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Ampicillin
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Ampicillin
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Metronidazole
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Metronidazole
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Metronidazole
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Piperacillin/Tazobactam
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Piperacillin/Tazobactam
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Piperacillin/Tazobactam
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Acyclovir
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Acyclovir
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Acyclovir
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Amphotericin B
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Amphotericin B
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Amphotericin B
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Ambisome
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Ambisome
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Ambisome
Description: Drug prescribed per routine medical care.
Study: NCT01837953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychodynamic Interpersonal Psychotherapy
Description: For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy (GPIP) condition, this intervention will consist of 16 weekly 90 minute sessions of GPIP. GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment. Examples of the patient's cyclical relational patterns (CRPs) that may underlie their symptoms are discussed and the patient will be encouraged to work on these in the groups. Therapists will be given a written summary of each patient's CRP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unguided Self-Help
Description: All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unguided Self-Help
Description: All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.
Study: NCT00289978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Description: Patients self-administered fingolimod 1.25 mg capsules orally once daily.
Study: NCT00491426

Intervention type: DRUG
Intervention: Anidulafungin
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Anidulafungin
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Anidulafungin
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Caspofungin
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Caspofungin
Description: Drug prescribed per routine medical care.

Intervention type: DRUG
Intervention: Caspofungin
Description: Drug prescribed per routine medical care.
Study: NCT01476644

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluation
Description: Biomicroscopy (look at front of eye), ophthalmoscopy (look at back of eye), visual acuity, visual fields, intraocular pressure, spectral domain optical coherence tomography, Pelli-Robson and the Spaeth-Richman Contrast Sensitivity tests

Intervention type: OTHER
Group type: OTHER
Intervention: Performance based measures
Description: Compressed Assessment of Ability Related to Vision (CAARV) items include: 1) computerized motion detection; 2) recognizing facial expressions; 3) reading street signs; and 4) finding objects in a room

Intervention type: OTHER
Group type: OTHER
Intervention: Subjective measures of vision-related quality of life
Description: National Eye Institute Visual Functioning Questionnaire 25 (NEI-VFQ-25) includes a series of questions pertaining to vision or feelings about a vision condition and the Modified Glaucoma Symptom Scale (MGSS) includes a series of questions pertaining to eye comfort.
Study: NCT00390234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study: NCT01511185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: A single dose of 7.5 mcg/kg administered subcutaneously in random order

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide
Description: A single dose of 7.5 mcg/kg administered subcutaneously in random order

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose administered subcutaneously in random order

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single dose administered subcutaneously in random order
Study: NCT00972855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Casodex®
Description: 50 mg Tablet
Study: NCT03551483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArtontheBrain
Description: The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArtontheBrain
Description: The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.

Intervention type: DEVICE
Group type: OTHER
Intervention: ArtontheBrain
Description: The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seniors Online Victoria
Description: The active control group will use a freely available website, which is updated daily with online games for seniors through an organization called Seniors Online Victoria (https://www.seniorsonline.vic.gov.au/services-information/games).
Study: NCT03582800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STS
Description: M0-M6 (run-in phase): medical care and follow-up as usual~M6-M12 (STS phase):~* Patients with iPPSD2 will be treated with subcutaneous infusion using a portable pump.~* Patients with dermatomyositis or systemic sclerosis will be treated with repeated injections every two weeks.~Patients will receive a maximal total number of 11 STS injections. M12: final visit (V5): clinical evaluation, photograph and CT scan of the treated lesion, pain and quality of life evaluation.
Study: NCT02130492

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG
Description: The intervention arm consists of treatment with increasing doses of \[18F\]-Fluorodeoxyglucose.
Study: NCT02156791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Study: NCT00813111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: 600mg SKY0402 instilled into breast pocket during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 200mg Bupivacaine HCl instilled into breast pocket during surgery
Study: NCT03050281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation/Cadaver lab
Description: The primary focus of this study is to determine whether the use of a comprehensive, combined, and simplified approach of using cadavers and simulation laboratories to train third-year medical students will have a beneficial effect on student performance in the OB-GYN and surgical clerkships.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lectures
Description: Standard Anatomy lectures were offered.
Study: NCT02554435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAM
Description: The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 A's counseling
Description: Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5 A's counseling
Description: Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
Study: NCT00832715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.